GlassScriptPhysician profile
Reece Bumgarner Moose
NPI 1528880192
$1,494.34
in general payments reported to CMS, 2019-2025
20 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $70.66 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $292.12 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $160.52 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $157.85 | 2025 | |
| Abbvie INC. | $154.06 | 2025 | |
| Pfizer INC. | $112.01 | 2025 | |
| Amgen INC. | $101.74 | 2025 | Otezla, Repatha |
| Lilly USA, LLC | $74.82 | 2025 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.84 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $61.44 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.08 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.04 | 2025 | Jardiance |
| Corcept Therapeutics | $38.94 | 2025 | Korlym |
| Exact Sciences Corporation | $29.64 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $22.74 | 2025 | Auvelity |
| Organon LLC | $22.33 | 2025 | Nexplanon |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $21.26 | 2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $19.53 | 2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $18.06 | 2025 | Heplisav-B |
| Currax Pharmaceuticals LLC | $16.26 | 2025 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $14.06 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reece Moose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.